¶ infliximab
Merged from 2 sources — review for redundancy.
¶ From immunology/
¶ Definition
A chimeric monoclonal antibody (75% human IgG1, 25% murine) that binds and neutralizes both soluble and membrane-bound TNF-α with high affinity (Kd ~10^-10 M), preventing TNF-α from activating TNFR1 and TNFR2 receptors. First anti-TNF biologic approved by FDA (1998 for Crohn's disease), revolutionized treatment of inflammatory bowel disease, rheumatoid arthritis, Ankylosing spondylitis, Psoriasis, and shows antidepressant effects in inflammatory Depression with C-reactive protein >5 mg/L. Represents proof-of-concept that blocking a single upstream cytokine can cascade into broad anti-inflammatory effects across multiple organ systems.
¶ Picture It
Imagine TNF-α as the fire alarm in a building that's been stuck in the "on" position for months—every time it rings, fire trucks arrive, hoses spray water, emergency crews smash windows, and the building sustains more damage from the rescue attempt than from any actual fire. Infliximab is like a specialized locksmith who doesn't just silence the alarm—it physically grabs the alarm lever (both the one mounted on the wall and the portable ones people are carrying) and holds them in place so they can't ring at all. But here's the catch: because the locksmith is partly built from foreign parts (25% mouse protein), the building's security system (your antibodies) sometimes recognizes the locksmith as an intruder and attacks them (anti-drug antibodies). When this happens, the locksmith gets escorted out (neutralized), and the alarm starts ringing again (loss of therapeutic response). Even when it works perfectly, blocking all fire alarms means real fires (like tuberculosis reactivation) can start without anyone noticing—which is why you must check for smoldering fires (latent TB screening) before hiring the locksmith.
¶ Mechanism
Infliximab neutralizes TNF-α through multiple coordinated mechanisms:
1. Direct Neutralization:
- Infliximab binds both soluble trimeric TNF-α and membrane-bound TNF-α (mTNF) with Kd ~10^-10 M
- Forms stable immune complexes that prevent TNF-α from binding to TNFR1 (p55) and TNFR2 (p75)
- Blocks TNFR1 → TRADD → TRAF2 → NF-κB activation cascade
- Prevents TNFR1-mediated RIPK1 → caspase-8 → apoptosis pathway
2. Reverse Signaling:
- Binding to membrane-bound TNF-α (mTNF) on macrophages and T cells triggers "outside-to-inside" signaling
- mTNF crosslinking → ERK1/2 phosphorylation → reduced IL-1β and Interleukin-6 production
- Induces apoptosis in TNF-producing cells via mTNF-mediated caspase activation
- Suppresses T cell proliferation through mTNF → p38 MAP kinase pathway
3. Antibody-Dependent Mechanisms:
- Fc portion of infliximab (human IgG1) binds FcγR on NK cells and macrophages
- Triggers ADCC (antibody-dependent cellular cytotoxicity) against mTNF-expressing cells
- Activates complement cascade → C1q binding → MAC formation → cell lysis (CDC)
- Particularly effective against activated monocytes and T cells in inflammatory bowel disease
4. Downstream Cascade Suppression:
- Blocked TNF-α → reduced NF-κB nuclear translocation → decreased transcription of:
- Reduced IL-6 → decreased acute phase response → falling CRP, SAA, fibrinogen
- In CNS: reduced microglial TNF-α → decreased indoleamine 2,3-dioxygenase (IDO) → less kynurenine pathway activation → improved serotonin availability
¶ Clinical Significance
Inflammatory Disease Treatment:
Infliximab validates the cytokine-targeted therapy paradigm—demonstrates that neutralizing a single upstream inflammatory mediator can produce dramatic clinical improvement across multiple autoimmune disease presentations. Response rates: 60-70% in inflammatory bowel disease, 55-65% in rheumatoid arthritis, 70-80% in Ankylosing spondylitis. In cPNI practice, response to anti-TNF therapy confirms that TNF-α-driven inflammation is the dominant pathophysiological mechanism (versus other inflammatory pathways like IL-17 or Interleukin-6).
Depression and Neuroinflammation:
Critical evidence linking peripheral inflammation to Depression: in patients with treatment-resistant depression and C-reactive protein >5 mg/L, infliximab shows antidepressant effects equivalent to SSRIs by reducing indoleamine 2,3-dioxygenase activity → decreased kynurenine pathway → improved serotonin synthesis and reduced quinolinic acid-mediated NMDA receptors activation in anterior cingulate cortex and basal ganglia. Supports inflammatory subtype classification in Depression (CRP >5 mg/L = immune-driven anhedonia/fatigue; CRP 
mg/L = unlikely to respond to anti-inflammatory approaches).
Metamodel Connections:
- Metamodel 0 (Evolutionary mismatch): Modern chronic infections and processed foods trigger persistent TNF-α elevation that ancestral immune systems never evolved to sustain
- Metamodel 1 (Chronic inflammation): Infliximab directly addresses the chronic low-grade inflammation driving metabolic, cardiovascular, and neuropsychiatric disease
- Selfish Immune System: TNF-α prioritizes immune defense over host wellbeing—blocking it improves metabolic flexibility, reduces insulin resistance, decreases cardiovascular events (30% reduction in inflammatory arthritis patients)
Clinical Decision Points:
- Pre-treatment screening mandatory: PPD or IGRA for latent TB (reactivation risk 5-10x normal), HBV/HCV serology, chest X-ray
- Monitor C-reactive protein and ESR every 8 weeks—failure to suppress below normal range suggests inadequate dosing or anti-drug antibodies
- Primary non-response (30-40% of patients): consider alternative cytokine pathways (IL-17, Interleukin-6), check TNF-α genetic polymorphisms
- Secondary loss of response (50% at 5 years): measure anti-infliximab antibodies and infliximab trough levels—if antibodies present, switch to fully human anti-TNF (adalimumab); if low trough, increase dose or frequency
- infectious disease risk: 2-4x increased risk of serious infections, particularly intracellular pathogens (TB, Listeria, Histoplasma) that require TNF-α for granuloma formation
Intervention Implications:
Response to infliximab suggests these supportive interventions may enhance outcomes:
- Omega-3 fatty acids (EPA >2g/day) to support specialized pro-resolving mediators (SPMs) synthesis
- Vitamin D optimization (>40 ng/mL) to support antimicrobial peptide production during immunosuppression
- Probiotic support (Faecalibacterium prausnitzii, Akkermansia-muciniphila) to reduce gut permeability and bacterial translocation
- Stress management to reduce HPA axis-mediated glucocorticoid resistance that can drive TNF-α production
¶ Key Facts
- Dosing: 5 mg/kg IV at weeks 0, 2, 6 (induction), then every 8 weeks (maintenance); can increase to 10 mg/kg or q6-week dosing if loss of response
- Pharmacokinetics: Half-life 9-12 days (longer than native IgG due to high-affinity FcRn binding); steady state after 3-4 infusions
- Response rates: 60-70% ACR50 in rheumatoid arthritis; 60% clinical remission in Crohn's disease; 30-50% complete mucosal healing in ulcerative colitis
- Depression efficacy: Significant antidepressant effect only in patients with baseline C-reactive protein >5 mg/L; no benefit if CRP mg/L (validates inflammatory depression subtype)
- Immunogenicity: Anti-drug antibodies develop in 10-30% of patients (higher without concomitant immunomodulator); chimeric structure (25% mouse protein) increases immunogenicity vs fully human antibodies
- Cost: $1,500-2,500 per infusion (varies by dose and healthcare system); annual cost $20,000-35,000 (most expensive in inflammatory disease armamentarium)
- Cardiovascular protection: 30-50% reduction in cardiovascular events in rheumatoid arthritis patients by reducing systemic inflammation, improving endothelial function, reducing insulin resistance
- Infection risk: 2-4x increased serious infections; TB reactivation risk 5-25x normal (highest in endemic areas); must screen for latent TB before initiating
- Contraindications: Active infectious disease, decompensated heart failure (NYHA class III-IV—TNF-α needed for cardiac remodeling), multiple sclerosis (TNF-α protects oligodendrocytes)
- Monitoring: CRP and ESR every 8-12 weeks (should normalize); CBC for cytopenias; LFTs for hepatotoxicity; anti-infliximab antibodies and trough levels if loss of response
¶ Connections
- TNF-α — chimeric monoclonal antibody that neutralizes both soluble and membrane-bound forms
- TNFR1 — blocks TNF-α binding to p55 receptor preventing NF-κB activation
- NF-κB — downstream transcription factor suppressed when TNF-α signaling blocked
- inflammatory bowel disease — first-line biologic for moderate-severe disease unresponsive to conventional therapy
- Crohn's disease — FDA-approved 1998; induces and maintains remission in 60% of patients
- ulcerative colitis — FDA-approved 2005; achieves mucosal healing in 30-50% of patients
- rheumatoid arthritis — reduces joint inflammation, prevents erosions, improves function in 55-65%
- Ankylosing spondylitis — dramatically improves spinal inflammation and mobility when NSAIDs fail
- Psoriasis — clears skin lesions in 70-80% by blocking keratinocyte TNF-α activation
- Depression — shows antidepressant effects in treatment-resistant patients with CRP >5 mg/L
- treatment-resistant depression — validates inflammatory subtype; effective when SSRIs fail in high-CRP patients
- C-reactive protein — patients with CRP >5 mg/L respond to antidepressant effects; mg/L unlikely to benefit
- kynurenine pathway — infliximab reduces IDO activity by blocking TNF-α-mediated microglial activation
- indoleamine 2,3-dioxygenase — TNF-α-induced enzyme suppressed by infliximab allowing serotonin restoration
- quinolinic acid — neurotoxic kynurenine metabolite reduced when TNF-α blocked
- anterior cingulate cortex — region where reduced quinolinic acid correlates with improved anhedonia
- Interleukin-6 — downstream cytokine indirectly reduced when TNF-α → NF-κB pathway blocked
- IL-1β — another downstream pro-inflammatory cytokine suppressed by infliximab
- IL-8 — neutrophil chemoattractant reduced when NF-κB activation prevented
- glucocorticoid resistance — can develop in chronic TNF-α states; blocking TNF-α restores glucocorticoid sensitivity
- insulin resistance — improves with infliximab treatment by reducing TNF-α-mediated IRS-1 serine phosphorylation
- cardiovascular disease — infliximab reduces events 30-50% in inflammatory arthritis by improving endothelial function
- chronic inflammation — infliximab addresses root cause by blocking upstream inflammatory driver
- infectious disease — major risk with infliximab due to TNF-α's role in granuloma formation and intracellular pathogen control
- tuberculosis — must screen for latent TB before infliximab; reactivation risk 5-25x baseline
- antibodies — anti-drug antibodies develop in 10-30%, causing loss of response and infusion reactions
- monoclonal antibody — infliximab is chimeric IgG1 class monoclonal antibody
- ADCC — antibody-dependent cellular cytotoxicity mechanism through Fc-FcγR interaction
- NK cells — mediate ADCC against membrane TNF-α-expressing cells when bound by infliximab
- gut permeability — improved in IBD as mucosal inflammation resolves with infliximab
- microbiome — composition shifts toward less inflammatory profile as gut inflammation controlled
¶ Module References
- Module 1
¶ From clinical-practice/
¶ Definition
Infliximab is a chimeric (75% human, 25% mouse) monoclonal IgG1 antibody that binds with high affinity (KD ~10⁻¹⁰ M) to both soluble and membrane-bound TNF-α, preventing receptor engagement and neutralizing TNF-α-driven inflammatory cascades. Clinically used for rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, Ulcerative Colitis, Psoriasis, and Ankylosing spondylitis, it has demonstrated antidepressant efficacy specifically in patients with baseline C-reactive protein >5 mg/L, providing mechanistic proof that inflammation can cause Depression in a definable patient subset.
¶ Picture It
Think of TNF-α as a town's emergency broadcast system that sounds alarm sirens during threats. The alarm (TNF-α) binds to receivers (TNFR1/TNFR2) on every building (cell), triggering coordinated defensive actions: businesses shut down (apoptosis), the fire department mobilizes (neutrophil recruitment), and factories switch to making emergency supplies (acute phase proteins). Infliximab is like a sound-dampening blanket thrown over the alarm towers—it physically wraps around the alarm signal before it can reach any receivers. The alarm keeps sounding, but no one hears it, so no emergency response launches. Crucially, this only helps buildings being damaged by too much alarm (high inflammation); in a quiet neighborhood (low C-reactive protein), adding soundproofing does nothing because there's no alarm to muffle. This explains why infliximab improves mood only in high-CRP depression—you can't fix a problem that isn't there.
¶ Mechanism
Molecular Cascade:
-
TNF-α neutralization: Infliximab Fab regions bind TNF-α homotrimers (3 TNF-α monomers) with 1:1 stoichiometry, sterically preventing TNF-α from engaging TNFR1 (55 kDa, death domain-containing) or TNFR2 (75 kDa, TRAF-binding)
-
Blocked TNFR1 signaling:
- TNFR1 → TRADD/FADD → Caspase-8 → Apoptosis (cell death pathway)
- TNFR1 → TRAF2/RIP1 → IKK complex (IKKα, IKKβ, NEMO) → IκB phosphorylation (Ser32/Ser36) → IκB ubiquitination/degradation → NF-κB (p65/p50) nuclear translocation → transcription of IL-1β, IL-6, IL-8, COX-2, iNOS, adhesion molecules (VCAM-1, ICAM-1)
-
Blocked TNFR2 signaling:
- TNFR2 → TRAF2 → JNK/p38 MAPK → AP-1 (c-Fos/c-Jun) activation → additional inflammatory cytokines and chemokines
-
Immune cell effects:
-
Brain-specific effects:
- Reduced peripheral TNF-α → decreased blood-brain barrier permeability → less peripheral cytokine entry
- Lower circulating TNF-α → reduced hepatic/macrophage IDO (indoleamine 2,3-dioxygenase) activation → less Tryptophan shunting to kynurenine pathway
- Decreased kynurenine → less 3-Hydroxykynurenine and quinolinic acid (NMDA agonist, neurotoxic)
- Preserved Tryptophan availability → maintained 5-HTP → 5-HT (serotonin) synthesis
- Reduced neuroinflammation → improved BDNF signaling in Hippocampus and anterior cingulate cortex
¶ Clinical Significance
Stratified psychiatry proof-of-concept: The 2013 Raison et al. trial demonstrated that infliximab (5 mg/kg IV at weeks 0, 2, 6) improved Depression scores (HDRS-17) only in patients with baseline C-reactive protein >5 mg/L (medium effect size d=0.57), with no benefit in CRP <5 mg/L patients. This provides Level 1 evidence that inflammation is a causal mechanism in a depression subtype, not just correlation.
cPNI metamodel integration:
- Metamodel 1 (chronic inflammation): Infliximab directly addresses low-grade-inflammation but only benefits the subset where inflammation is the primary driver of mood pathology
- Selfish immune system: High TNF-α reflects immune system prioritizing defense over brain function; blocking TNF-α forces resource reallocation back to brain metabolism
- Evolutionary mismatch: Chronic TNF-α elevation (from obesity, gut dysbiosis, chronic stress) is non-adaptive; ancestral acute infections resolved, whereas modern metaflammation persists indefinitely
Clinical decision-making:
- Screen with high-sensitivity CRP: Patients with treatment-resistant depression + CRP >5 mg/L (or even >3 mg/L) may have inflammation-driven depression requiring anti-inflammatory intervention
- Not first-line for depression: Infliximab carries risks (infection, malignancy, infusion reactions); reserve for severe cases unresponsive to standard therapy
- Lifestyle as TNF-α blockers: Exercise, Omega-3 fatty acids (EPA/DHA), Curcumin, sleep optimization, gut barrier repair, weight loss all reduce TNF-α without biologics—these are first-line in cPNI
- Autoimmune depression overlap: Patients with comorbid rheumatoid arthritis, inflammatory bowel disease, or Psoriasis treated with infliximab often report mood improvement independent of physical symptom relief
Biomarker thresholds:
- CRP >5 mg/L: Predicts infliximab response in depression
- CRP >10 mg/L: High-grade inflammation, urgent need for anti-inflammatory approach
- IL-6 >10 pg/mL: Often co-elevated with high TNF-α, alternative target
- Neutrophil-lymphocyte ratio >3: Marker of systemic inflammatory burden
Intervention implications:
- If CRP <5 mg/L, focus on other depression drivers: HPA-axis dysregulation, neurotransmitter depletion, gut-brain axis, circadian disruption
- If CRP 3-5 mg/L, trial aggressive lifestyle anti-inflammatory protocol before considering biologics
- If CRP >5 mg/L + depression, consider anti-inflammatory augmentation: EPA 2-4 g/day, Curcumin 1 g/day, anti-inflammatory diet, gut microbiome restoration
¶ Key Facts
- Chimeric antibody: 75% human constant regions, 25% murine variable regions (reduces immunogenicity vs. pure mouse antibodies)
- Binding affinity: KD ~10⁻¹⁰ M for TNF-α (extremely tight binding)
- Dosing: 5 mg/kg IV infusion at weeks 0, 2, 6, then every 8 weeks for maintenance
- Half-life: 8-10 days (allows 6-8 week dosing intervals)
- Antidepressant efficacy: Only in patients with baseline C-reactive protein >5 mg/L (Raison et al., 2013)
- No benefit in low-inflammation depression: CRP <5 mg/L patients show no mood improvement with infliximab
- Mechanism selectivity: Blocks both soluble TNF-α trimers and membrane-bound TNF-α (important for immune cell interactions)
- FDA-approved indications: rheumatoid arthritis, Crohn's disease, Ulcerative Colitis, Ankylosing spondylitis, plaque Psoriasis, psoriatic arthritis
- Risks: Increased infection (TB reactivation, fungal, opportunistic), lymphoma risk, infusion reactions, antibody formation (ATI—antibodies to infliximab)
- Depression trial results: 30% reduction in HDRS-17 scores vs. placebo in high-CRP group after 12 weeks
¶ Connections
- TNF-α — infliximab's direct molecular target; blocks both soluble and membrane-bound forms
- C-reactive protein — CRP >5 mg/L predicts infliximab antidepressant response; essential biomarker for patient selection
- NF-κB — infliximab prevents TNF-α-driven NF-κB activation, blocking transcription of inflammatory genes
- IL-6 — downstream of TNF-α-NF-κB cascade; infliximab indirectly reduces IL-6 production
- IL-1β — co-regulated with TNF-α via NF-κB; infliximab reduces IL-1β by blocking upstream TNF-α
- IDO — TNF-α induces IDO in macrophages/liver; infliximab blocks this, preserving tryptophan for serotonin synthesis
- kynurenine pathway — infliximab dampens inflammation-driven kynurenine production by reducing IDO activation
- quinolinic acid — neurotoxic NMDA agonist produced via kynurenine pathway; reduced when TNF-α is blocked
- Depression — infliximab treats inflammatory subtype (CRP >5 mg/L); demonstrates causality of inflammation → mood pathology
- treatment-resistant depression — infliximab effective in TRD with high inflammation; suggests stratified treatment approach
- BDNF — neuroinflammation suppresses BDNF; infliximab may restore BDNF signaling in hippocampus
- anterior cingulate cortex — brain region affected by inflammatory cytokines; infliximab may normalize ACC function in high-CRP depression
- Hippocampus — TNF-α inhibits hippocampal neurogenesis; infliximab may restore neuroplasticity
- gut-brain axis — infliximab used for IBD; gut inflammation drives systemic TNF-α affecting brain
- inflammatory bowel disease — primary indication for infliximab; patients often experience mood improvement
- rheumatoid arthritis — another indication; RA patients have elevated depression rates linked to TNF-α
- COX-2 — TNF-α induces COX-2 via NF-κB; infliximab blocks this, reducing prostaglandin production
- Glucocorticoid resistance — chronic TNF-α impairs glucocorticoid receptor function; infliximab may restore cortisol sensitivity
- IFN-alpha — like TNF-α, IFN-α drives depression via IDO/kynurenine; infliximab targets TNF-specific pathway
- STAR*D trial — landmark depression trial showing poor SSRI response in many patients; supports need for biomarker-guided approaches like anti-TNF in high-CRP subset
- EPA — omega-3 fatty acid that reduces TNF-α production; natural adjunct or alternative to infliximab
- Curcumin — inhibits NF-κB activation; synergistic with TNF-α blockade
- Exercise — reduces TNF-α expression and enhances anti-inflammatory signaling; lifestyle TNF-α blocker
- chronic inflammation — infliximab addresses chronic low-grade inflammation when TNF-α is primary driver
¶ Module References
- Module 1: Depression and inflammation, IDO/kynurenine pathway, CRP as depression biomarker, treatment-resistant depression mechanisms